Abstract: A dynamically correcting cache memory is capable of correcting itself by dynamically reflecting any modifications inflicted upon the data/information to be stored therein. Further, the cache memory is refreshed at predetermined time intervals and also based on predetermined criteria, thereby ensuring a high cache hit rate. The dynamically correcting cache memory is bypassed for certain user queries prioritized based on a predetermined criteria. The dynamically correcting cache manages an inventory shared between multiple non-cooperative web-based, computer-implemented platforms. The dynamically correcting cache is directed to reducing caching errors in web based computer implemented platforms. The dynamically correcting cache responds to rapid changes associated with (online) behavior of users accessing web based computer implemented platforms by dynamically configuring TTL (Time-To-Live) values, in order to ensure that the data/information stored in the cache memory remains accurate.

Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.

Abstract: The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.

Abstract: An ingestible device includes a sample chamber configured to hold a sample, the sample chamber including a base having an aperture; a fluorometer separated from the sample chamber by the sample chamber base, the fluorometer including (I) a light source configured to emit excitation light, (II) a light guide configured to guide the excitation light from the light source to the sample, (III) a photodetector configured to detect emission light generated via the interaction of the excitation light with the sample. The photodetector is configured to receive the emission light from the sample through the aperture. Additionally, the fluorometer includes (IV) an emission filter between the aperture and the photodetector, the emission filter configured to (i) transmit the emission light incident thereon, and (ii) block excitation light incident thereon. In addition, the ingestible device includes a housing that houses the sample chamber and the fluorometer.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TNF inhibitor.

Abstract: The present invention provides methods for selecting a suitable anticancer therapy, and for identifying and predicting response for the treatment of a gastric cancer.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TLR agonist.

Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.

Abstract: Polymers comprising first and second fluorescent or colored moieties on the polymer backbone and two or more charged moieties on the polymer backbone between the first and second colored or fluorescent moieties are provided. The polymers are useful as fluorescent or colored dyes. Methods associated with preparation and use of such polymers are also provided.

Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble ?4?7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.

Abstract: The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. The present invention further provides methods for the rational selection of therapy with one or more anticancer drugs tailored to target signal transduction pathway components with dysregulated expression and/or activation levels in patients with somatic mutations in an oncogene.

Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.

Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

Abstract: The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn's disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-?4?7 integrin drug.

Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I), including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, L1, L2, L3, L4, L5, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

Abstract: Compositions comprising a polymeric dye and a cyclodextrin are provided. Methods associated with preparation and use of such compounds, for example in methods for detection of any analyte molecule, are also provided.

Abstract: Disclosed herein are methods and composition of improving accuracy of cancer detection and enhancing therapeutic outcomes. The compositions, methods and systems described herein facilitate assessing risk assessment of cancer.

Abstract: Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.

Abstract: The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNF? inhibitor for the treatment of a TNF?-mediated disease or disorder.

Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether a sample from an individual is an IBS sample or a healthy control sample using a statistical algorithm. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.